DSGN
NASDAQDesign Therapeutics Inc.
News · 26 weeks290%
2025-10-262026-04-19
Mix1390d
- SEC Filings7(54%)
- Other3(23%)
- Insider2(15%)
- Analyst1(8%)
Latest news
25 items- SECSEC Form DEFA14A filed by Design Therapeutics Inc.DEFA14A - Design Therapeutics, Inc. (0001807120) (Filer)
- SECSEC Form DEF 14A filed by Design Therapeutics Inc.DEF 14A - Design Therapeutics, Inc. (0001807120) (Filer)
- INSIDERSEC Form 4 filed by Shapiro David4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shapiro David3 - Design Therapeutics, Inc. (0001807120) (Issuer)
- SECDesign Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- ANALYSTJefferies initiated coverage on Design Therapeutics with a new price targetJefferies initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00
- SECSEC Form S-8 filed by Design Therapeutics Inc.S-8 - Design Therapeutics, Inc. (0001807120) (Filer)
- SECSEC Form 10-K filed by Design Therapeutics Inc.10-K - Design Therapeutics, Inc. (0001807120) (Filer)
- SECDesign Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- PRDesign Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business UpdatesTrials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. "The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC® portfolio," said Pratik Sha
- PRDesign Therapeutics to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m. ET (virtual)Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 2:20 p.m. ET in Miami, FL Live webcasts of each presentation will be available here and in the investors section of the company's website at www.designtx.com.The webcasts will be archived for at least 30 days fo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.SCHEDULE 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
- SECSEC Form 8-K filed by Design Therapeutics Inc.8-K - Design Therapeutics, Inc. (0001807120) (Filer)
- ANALYSTOppenheimer initiated coverage on Design Therapeutics with a new price targetOppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00
- INSIDERSEC Form 4 filed by Chief Medical Officer Storgard Chris4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Jeffries Sean4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Burgess Julie4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by Director Gover Justin D.4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Chairperson Shah Pratik4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- INSIDERSEC Form 4 filed by President, CEO and Chairperson Shah Pratik4 - Design Therapeutics, Inc. (0001807120) (Issuer)
- ANALYSTDesign Therapeutics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Design Therapeutics from Market Perform to Outperform and set a new price target of $14.00
- ANALYSTCraig Hallum initiated coverage on Design Therapeutics with a new price targetCraig Hallum initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00
- PRDesign Therapeutics to Participate in Upcoming Investor ConferencesCARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NYEvercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gables, FL Live webcasts of each fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcasts will be archived
- ANALYSTDesign Therapeutics upgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts upgraded Design Therapeutics from Sector Perform to Outperform and set a new price target of $13.00
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Design Therapeutics Inc.SCHEDULE 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)